Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cutler

Showing results (121-130 of 217) with videos related to

Pageof 22
Sort By:
The EMBO Journal|November 15, 1995
Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activationJ E Damen, H Wakao, A Miyajima, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 26, 2013
Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary diseaseTeddy Kosoglou, James Hubbell, Fengjuan Xuan, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|August 7, 2019
Long-term Outcomes of Balloon Dilation for Persistent Eustachian Tube DysfunctionJeffrey L Cutler, Ted A Meyer, Shaun A Nguyen, et al.
Clinical Pharmacology in Drug Development|April 14, 2017
No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy VolunteersMatt S Anderson, Teddy Kosoglou, Paul Statkevich, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trialTeddy Kosoglou, Thomas L Hunt, Fengjuan Xuan, et al.
Clinical Pharmacology and Therapeutics|February 11, 2000
In vivo effects of interleukin-10 on human cytochrome P450 activityJ C Gorski, S D Hall, P Becker, et al.
Pharmacotherapy|January 27, 2004
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic studyMichelle A Rudek, Ross C Donehower, Paul Statkevich, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomideP Beale, I Judson, S Moore, et al.
Psychiatric Services (Washington, D.C.)|September 15, 1998
A three-decade perspective on community and public psychiatry training in OregonR Goetz, D L Cutler, D Pollack, et al.
Journal of Comparative Effectiveness Research|May 23, 2019
An evidence-based model to consolidate medication adherence cost estimation: the medication adherence cost estimation frameworkRachelle L Cutler, Naomi Van der Linden, Shalom I Charlie Benrimoj, et al.
Pageof 22

Showing results (121-130 of 217) with videos related to

Sort By:
Pageof 22
The EMBO Journal|November 15, 1995
Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activationJ E Damen, H Wakao, A Miyajima, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 26, 2013
Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary diseaseTeddy Kosoglou, James Hubbell, Fengjuan Xuan, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|August 7, 2019
Long-term Outcomes of Balloon Dilation for Persistent Eustachian Tube DysfunctionJeffrey L Cutler, Ted A Meyer, Shaun A Nguyen, et al.
Clinical Pharmacology in Drug Development|April 14, 2017
No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy VolunteersMatt S Anderson, Teddy Kosoglou, Paul Statkevich, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trialTeddy Kosoglou, Thomas L Hunt, Fengjuan Xuan, et al.
Clinical Pharmacology and Therapeutics|February 11, 2000
In vivo effects of interleukin-10 on human cytochrome P450 activityJ C Gorski, S D Hall, P Becker, et al.
Pharmacotherapy|January 27, 2004
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic studyMichelle A Rudek, Ross C Donehower, Paul Statkevich, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomideP Beale, I Judson, S Moore, et al.
Psychiatric Services (Washington, D.C.)|September 15, 1998
A three-decade perspective on community and public psychiatry training in OregonR Goetz, D L Cutler, D Pollack, et al.
Journal of Comparative Effectiveness Research|May 23, 2019
An evidence-based model to consolidate medication adherence cost estimation: the medication adherence cost estimation frameworkRachelle L Cutler, Naomi Van der Linden, Shalom I Charlie Benrimoj, et al.
Pageof 22